Received Aug 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 3 | — | — |
autoimmune disease; developed tinnitus 2 weeks after 1st covid shot. It's worsened after 2nd and 3rd shots.; This is a spontaneous report received from a Consumer or other non HCP from medical information team. A patient (age and gender not provided) received BNT162b2 (BNT162B2 NOS), as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 nos (DOSE 1, SINGLE), for COVID-19 immunization, reaction(s): "Tinnitus"; Bnt162b2 nos (DOSE 2, SINGLE), for COVID-19 immunization, reaction(s): "autoimmune disease", "It's worsened after 2nd and 3rd shots", "Tinnitus". The following information was reported: AUTOIMMUNE DISORDER (medically significant), outcome "unknown", described as "autoimmune disease"; TINNITUS (non-serious), outcome "unknown", described as "developed tinnitus 2 weeks after 1st covid shot. It's worsened after 2nd and 3rd shots". Clinical course: Patient developed tinnitus 2 weeks after 1st covid shot. It was worsened after 2nd and 3rd shots. Patient developed autoimmune disease after 3 covid vaccines. Patient developed autoantibodies but had no diagnosis after 3 covid shots. The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202500158063 same patient/reporter, different vaccine dose/AE;